Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against Chlamydia pneumoniae
- 8 October 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (21) , 7664-7674
Abstract
Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer’s disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 μM, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 μM against CWL-029 and 6.3 μM against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.Keywords
This publication has 59 references indexed in Scilit:
- In Vitro Activity of CEM-101, a New Fluoroketolide Antibiotic, against Chlamydia trachomatis and Chlamydia ( Chlamydophila ) pneumoniaeAntimicrobial Agents and Chemotherapy, 2010
- Chlamydophila pneumoniae Infection Leads to Smooth Muscle Cell Proliferation and Thickening in the Coronary Artery without Contributions from a Host Immune ResponseThe American Journal of Pathology, 2010
- Evidence that HumanChlamydia pneumoniaeWas Zoonotically AcquiredJournal of Bacteriology, 2009
- Chlamydophila pneumoniaeClinical Microbiology and Infection, 2009
- Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity RelationshipsJournal of Medicinal Chemistry, 2008
- Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infectionRespiratory Research, 2008
- Chlamydia pneumoniae -Induced Macrophage Foam Cell Formation Is Mediated by Toll-Like Receptor 2Infection and Immunity, 2007
- Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycleFEBS Letters, 2007
- Increased Aortic Intima-Media Thickness in 11-Year-Old Healthy Children With Persistent Chlamydia pneumoniae SeropositivityArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Serologic markers for Chlamydia pneumoniae in asthmaAnnals of Allergy, Asthma & Immunology, 2000